Impact of mirabegron versus solifenacin on autonomic function and arterial stiffness in female overactive bladder syndrome: a randomized controlled trial

被引：0
作者：
Sheng-Mou Hsiao
Fung-Chao Tu
Ta-Chen Su
Pei-Chi Wu
Ho-Hsiung Lin
机构：
[1] Yuan Ze University,Graduate School of Biotechnology and Bioengineering
[2] Far Eastern Memorial Hospital,Department of Obstetrics and Gynecology
[3] National Taiwan University College of Medicine and Hospital,Department of Obstetrics and Gynecology
[4] National Taiwan University College of Medicine and Hospital,Department of Internal Medicine
来源：
Scientific Reports | / 12卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The study aims to elucidate the impact of mirabegron versus solifenacin on autonomic function and peripheral arterial conditions in women with overactive bladder syndrome (OAB). All consecutive women with OAB were randomized to receive 12 weeks of mirabegron 25 mg or solifenacin 5 mg once per day. Heart rate variability, cardio-ankle vascular index, ankle-brachial pressure index, blood pressure, and heart rate were compared between the two groups. There were 87 women (mirabegron, n = 43; and solifenacin, n = 44) who completed 12-week treatment and underwent heart rate variability examination. Systolic blood pressure (median: − 4.5 to − 5.5 mmHg) and diastolic blood pressure (median: − 0.5 to − 3.5 mmHg) decreased after solifenacin treatment, and heart rate (median: + 2 bpm) increased after mirabegron treatment, despite of no between-group difference. In addition, posttreatment heart rate variability, cardio-ankle vascular index, and ankle-brachial pressure index did not differ compared with baseline; and there were no between-group differences. In conclusion, solifenacin might decrease blood pressure, and mirabegron might increase heart rate. Nonetheless, there were no significant impacts of 12-week mirabegron versus solifenacin treatment on autonomic function and arterial stiffness.
引用
收藏
相关论文
共 66 条
[1]  
Haylen BT(2010)An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction Int. Urogynecol. J. 21 5-26
[2]  
Drake MJ(2001)Model of peripheral autonomous modules and a myovesical plexus in normal and overactive bladder function Lancet 358 401-403
[3]  
Mills IW(2006)Cardiac adrenoceptors: Physiological and pathophysiological relevance J. Pharmacol. Sci. 100 323-337
[4]  
Gillespie JI(2018)Cardiovascular effects of antimuscarinic agents and beta 3-adrenergic receptor agonist for the treatment of overactive bladder Expert Opin. Drug. Saf. 17 487-497
[5]  
Brodde OE(2017)The β3-adrenoceptor agonist mirabegron increases human atrial force through β1-adrenoceptors: An indirect mechanism? Br. J. Pharmacol. 174 2706-2715
[6]  
Bruck H(2019)The probability of re-treatment after discontinuation of a 3-month versus a 6-month course of solifenacin for female overactive bladder: A prospective randomized controlled study Maturitas 126 11-17
[7]  
Leineweber K(2011)Cardiac effects of muscarinic receptor antagonists used for voiding dysfunction Br. J. Clin. Pharmacol. 72 186-196
[8]  
Rosa GM(2004)Vasodilatory effects of cholinergic agonists are greatly diminished in aorta from M3R−/− mice Eur. J. Pharmacol. 493 127-132
[9]  
Mo W(2014)Autonomic dysfunction and arterial stiffness in female overactive bladder patients and antimuscarinics related effects Maturitas 79 65-69
[10]  
Michel MC(2005)Analysis of heart rate variability in female patients with overactive bladder Urology 65 1109-1112
1234567